These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
625 related articles for article (PubMed ID: 9155045)
1. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045 [TBL] [Abstract][Full Text] [Related]
2. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509 [TBL] [Abstract][Full Text] [Related]
3. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754 [TBL] [Abstract][Full Text] [Related]
4. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index]. Xu QZ; Liu F; Lu DH; Yu SZ; Yang H Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073 [TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions. Souza PE; Mesquita RA; Gomez RS Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786 [TBL] [Abstract][Full Text] [Related]
8. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation. Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933 [TBL] [Abstract][Full Text] [Related]
11. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113 [TBL] [Abstract][Full Text] [Related]
12. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors]. Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789 [TBL] [Abstract][Full Text] [Related]
15. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685 [TBL] [Abstract][Full Text] [Related]
16. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947 [TBL] [Abstract][Full Text] [Related]
19. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis. Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823 [TBL] [Abstract][Full Text] [Related]
20. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions. Brustmann H; Naudé S Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]